Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 7
1981 6
1982 7
1983 10
1984 8
1985 6
1986 7
1987 2
1988 4
1989 2
1990 1
1991 3
1993 1
1994 3
1995 8
1996 7
1997 3
1998 8
1999 7
2000 2
2001 11
2002 8
2003 7
2004 9
2005 10
2006 9
2007 6
2008 13
2009 26
2010 30
2011 20
2012 20
2013 11
2014 16
2015 18
2016 20
2017 11
2018 7
2019 8
2020 9
2021 10
2022 10
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

363 results
Results by year
Filters applied: . Clear all
Page 1
Fenofibric acid.
Rath NP, Haq W, Balendiran GK. Rath NP, et al. Acta Crystallogr C. 2005 Feb;61(Pt 2):o81-4. doi: 10.1107/S0108270104032573. Epub 2005 Jan 15. Acta Crystallogr C. 2005. PMID: 15695917
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety inste …
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid …
Fenofibric acid for hyperlipidemia.
Saurav A, Kaushik M, Mohiuddin SM. Saurav A, et al. Expert Opin Pharmacother. 2012 Apr;13(5):717-22. doi: 10.1517/14656566.2012.658774. Epub 2012 Mar 9. Expert Opin Pharmacother. 2012. PMID: 22404421 Review.
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, es …
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fen …
Fenofibric Acid (trilipix).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 May 4;51(1311):33-4. Med Lett Drugs Ther. 2009. PMID: 19417718 No abstract available.
Lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 11;61(1565):17-24. Med Lett Drugs Ther. 2019. PMID: 30845106 No abstract available.
In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
Malátková P, Kanavi M, Nobilis M, Wsól V. Malátková P, et al. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4. Chem Biol Interact. 2016. PMID: 27599626
Fenofibric acid is a hypolipidemic drug that is used as an active ingredient per se or is administered in the form of fenofibrate that releases fenofibric acid after absorption. The metabolism of fenofibric acid is mediated primarily by g …
Fenofibric acid is a hypolipidemic drug that is used as an active ingredient per se or is administered in the form of fenofibr …
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP, Keating GM. Yang LP, et al. Am J Cardiovasc Drugs. 2009;9(6):401-9. doi: 10.2165/11203920-000000000-00000. Am J Cardiovasc Drugs. 2009. PMID: 19929038
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. ...Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric aci …
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. . …
Chemoselective Reduction of Fenofibric Acid to Alcohol in the Presence of Ketone by Mixed Anhydride and Sodium Borohydride.
Majethia GN, Haq W, Balendiran GK. Majethia GN, et al. Int J Org Chem (Irvine). 2022 Jun;12(2):116-125. doi: 10.4236/ijoc.2022.122010. Epub 2022 Jun 30. Int J Org Chem (Irvine). 2022. PMID: 35919104 Free PMC article.
A highly efficient and facile protocol for the selective reduction of carboxylic acid of Fenofibric acid to corresponding alcohol was developed. The selective reduction was carried out by activation of carboxylic acid by mixed anhydride followed by the …
A highly efficient and facile protocol for the selective reduction of carboxylic acid of Fenofibric acid to correspondi …
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. Zhu T, et al. J Clin Pharmacol. 2010 Aug;50(8):914-21. doi: 10.1177/0091270009354995. Epub 2010 Feb 9. J Clin Pharmacol. 2010. PMID: 20145261 Clinical Trial.
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers. ...Serial blood samples were collected for 1 …
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and f …
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Massin P, Peto T, Ansquer JC, Aubonnet P, MacuFEN Study Investigators FT. Massin P, et al. Ophthalmic Epidemiol. 2014 Oct;21(5):307-17. doi: 10.3109/09286586.2014.949783. Epub 2014 Aug 18. Ophthalmic Epidemiol. 2014. PMID: 25133794 Clinical Trial.
PURPOSE: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. ...Triglycerides decreased by 23% after fenofibric …
PURPOSE: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric …
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A, Kamata S, Akahane M, Machida Y, Uchii K, Shiiyama Y, Habu Y, Miyawaki S, Kaneko C, Oyama T, Ishii I. Honda A, et al. Int J Mol Sci. 2022 Apr 25;23(9):4726. doi: 10.3390/ijms23094726. Int J Mol Sci. 2022. PMID: 35563117 Free PMC article.
Although the efficacy and efficiency highly varied between agonists, assay types, and PPAR subtypes, the three fibrates, except fenofibric acid that did not affect PPARdelta-mediated transactivation and coactivator recruitment, activated all PPAR subtypes in those a …
Although the efficacy and efficiency highly varied between agonists, assay types, and PPAR subtypes, the three fibrates, except fenofibri …
363 results